P53 family and cellular stress responses in cancer

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Pflaum, Johanna ^a   Schlosser, Sophie ^a   Müller, Martina ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Apoptosis; Cancer; Cellular stress; Chemosensitivity; p53; p63; p73

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL) QUINAZOLINE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; CD5 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH RECEPTOR; DICER; FAS LIGAND; GLUTAMINASE; HUR PROTEIN; ISOPROTEIN; NUTLIN 1; NUTLIN 2; NUTLIN 3; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN BAK; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53; PROTEIN P63; PROTEIN P73; PUMA PROTEIN; TRANSCRIPTION FACTOR E2F1; TRYPTAMINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CHEMOSENSITIVITY; CHROMOSOME 17; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DNA BINDING; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; EXON; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GERMLINE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HEPATOCELLULAR CARCINOMA CELL LINE; HYPOXIA; IONIZING RADIATION; METASTASIS; NEOPLASM; NERVE CELL DIFFERENTIATION; OVARY CANCER; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

EID: 84907854322     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00285     Document Type: Article

References (237)

1. Ashley DJ. The two "hit" and multiple "hit" theories of carcinogenesis. Br. J. Cancer 1969; 23(2):313-28.
2. Karakosta A, Golias C, Charalabopoulos A, Peschos D, Batistatou A, Charalabopoulos K. Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. J. Exp. Clin. Cancer Res. 2005; 24(4):505-14.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646-74.
4. Clydesdale GJ, Dandie GW, Muller HK. Ultraviolet light induced injury: immunological and inflammatory effects. Immunol. Cell Biol. 2001; 79(6):547-68.
5. Kamb A. Cancer. Sun protection factor p53. Nature 1994; 372(6508):730-1.
6. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372(6508):773-6.
7. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int. J. Radiat. Biol. 1994; 65(1):27-33.
8. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 2010; 40(2):294-309.
9. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350(6317):429-31.
10. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350(6317):427-8.
11. Itoh M, Tsuji T, Nakamura H, Yamaguchi K, Fuchikami J, Takahashi M et al. Systemic effects of acute cigarette smoke exposure in mice. Inhal Toxicol 2014; 26(8):464-73.
12. Barzilai A, Yamamoto K. DNA damage responses to oxidative stress. DNA Repair (Amst.) 2004; 3(8-9):1109-15.
13. Rotblat B, Grunewald, Thomas G P, Leprivier G, Melino G, Knight RA. Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers. Oncotarget 2013; 4(12):2577-90.
14. Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ. 2014; 21(1):26-38.
15. Haigis KM, Sweet-Cordero A. New insights into oncogenic stress. Nat. Genet. 2011; 43(3):177-8.
16. Belyi VA, Ak P, Markert E, Wang H, Hu W, Puzio-Kuter A et al. The origins and evolution of the p53 family of genes. Cold Spring Harb Perspect Biol 2010; 2(6):a001198.
17. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim. Biophys. Acta 2009; 1787(5):414-20.
18. Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol. 2010; 20(1):14-24.
19. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 2005; 17(6):631-6.
20. Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet. 2012; 28(3):128-36.
21. Christmann M, Kaina B. Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res. 2013; 41(18):8403-20.
22. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71(4):587-97.
23. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006; 13(6):941-50.
24. Murray-Zmijewski F, Lane DP, Bourdon J. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006; 13(6):962-72.
25. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 2009; 9(10):749-58.
26. Müller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T. One, two, three--p53, p63, p73 and chemosensitivity. Drug Resist. Updat. 2006; 9(6):288-306.
27. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 2005; 24(13):2458- 71.
28. Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K et al. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res. 1999; 59(12):2781-6.
29. Müller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 2005; 12(12):1564-77.
30. Dötsch V, Bernassola F, Coutandin D, Candi E, Melino G. p63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol 2010; 2(9):a004887.
31. Schilling T, Schleithoff ES, Kairat A, Melino G, Stremmel W, Oren M et al. Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem. Biophys. Res. Commun. 2009; 387(2):399-404.
32. Candi E, Agostini M, Melino G, Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum. Mutat. 2014; 35(6):702-14.
33. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398(6729):714-8.
34. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404(6773):99-103.
35. Vilgelm A, El-Rifai W, Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist. Updat. 2008; 11(4-5):152-63.
36. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3(6):673-82.
37. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75(6):1169-78.
38. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J. Immunol. 1988; 141(8):2629-34.
39. Lavrik IN. Systems biology of death receptor networks: live and let die. Cell Death Dis 2014; 5:e1259.
40. Galluzzi L, Bravo-San Pedro, J M, Vitale I, Aaronson SA, Abrams JM, Adam D et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 2014.
41. McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 2013; 5(4):a008656.
42. Ashkenazi A, Salvesen G. Regulated Cell Death: Signaling and Mechanisms. Annu. Rev. Cell Dev. Biol. 2014.
43. Kumar S. Caspase function in programmed cell death. Cell Death Differ. 2007; 14(1):32-43.
44. Elkholi R, Floros KV, Chipuk JE. The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes Cancer 2011; 2(5):523-37.
45. Ding J, Mooers, Blaine H M, Zhang Z, Kale J, Falcone D, McNichol J et al. After embedding in membranes antiapoptotic Bcl-XL protein binds both Bcl-2 homology region 3 and helix 1 of proapoptotic Bax protein to inhibit apoptotic mitochondrial permeabilization. J. Biol. Chem. 2014; 289(17):11873-96.
46. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol. Cell 2010; 37(3):299-310.
47. Bourdon J, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005; 19(18):2122-37.
48. Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A et al. Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript. FEBS Lett. 2010; 584(21):4463-8.
49. Surget S, Khoury MP, Bourdon J. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther 2013; 7:57-68.
50. Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H et al. p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ. 2011; 18(2):248-58.
51. Ungewitter E, Scrable H. Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev. 2010; 24(21):2408-19.
52. Muller, Patricia A J, Vousden KH. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities. Cancer Cell 2014; 25(3):304-17.
53. Mavinahalli JN, Madhumalar A, Beuerman RW, Lane DP, Verma C. Differences in the transactivation domains of p53 family members: a computational study. BMC Genomics 2010; 11 Suppl 1:S5.
54. Sauer M, Bretz AC, Beinoraviciute-Kellner R, Beitzinger M, Burek C, Rosenwald A et al. C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity. Nucleic Acids Res. 2008; 36(6):1900-12.
55. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 1969; 71(4):747-52.
56. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 2003; 21(3):313-20.
57. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356(6366):215-21.
58. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009; 9(6):400-14.
59. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69(7):1237-45.
60. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain. Science 1996; 274(5289):948-53.
61. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387(6630):296-9.
62. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 2000; 20(22):8458-67.
63. Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 1994; 8(15):1739-49.
64. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 2003; 13(1):49-58.
65. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol. Cancer Res. 2003; 1(14):1001-8.
66. Perry ME. The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol 2010; 2(1):a000968.
67. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83(6):993-1000.
68. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17(17):5001-14.
69. Sherr CJ. An Arf(GFP/GFP) reporter mouse reveals that the Arf tumor suppressor monitors latent oncogenic signals in vivo. Cell Cycle 2004; 3(3):239-40.
70. Lin AW, Lowe SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. U.S.A. 2001; 98(9):5025-30.
71. Gregory MA, Qi Y, Hann SR. The ARF tumor suppressor: keeping Myc on a leash. Cell Cycle 2005; 4(2):249-52.
72. Cong F, Zou X, Hinrichs K, Calame K, Goff SP. Inhibition of v-Abl transformation by p53 and p19ARF. Oncogene 1999; 18(54):7731-9.
73. Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G et al. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ. 2013; 20(11):1485-97.
74. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1999; 1(1):20-6.
75. Kamijo T, Bodner S, van de Kamp, E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res. 1999; 59(9):2217-22.
76. Rowland BD, Denissov SG, Douma S, Stunnenberg HG, Bernards R, Peeper DS. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell 2002; 2(1):55-65.
77. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol. 1998; 18(11):6457-73.
78. Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2010; 2(8):a000935.
79. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 2003; 11(3):577-90.
80. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem. 2006; 281(13):8600-6.
81. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303(5660):1010-4.
82. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004; 6(5):443-50.
83. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol. 2005; 7(2):165-71.
84. Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V. p53: The barrier to cancer stem cell formation. FEBS Lett. 2014.
85. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011; 17(3):313-9.
86. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 1998; 4(7):839-43.
87. Schmale H, Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene 1997; 15(11):1363-7.
88. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 1998; 2(3):305-16.
89. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90(4):809-19.
90. Harms KL, Chen X. The C terminus of p53 family proteins is a cell fate determinant. Mol. Cell. Biol. 2005; 25(5):2014-30.
91. Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M. Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. Proc. Natl. Acad. Sci. U.S.A. 2011; 108(9):3624-9.
92. Beyer U, Dobbelstein M. Non-hominid TP63 lacks retroviral LTRs but contains a novel conserved upstream exon. Cell Cycle 2011; 10(12):1905-11.
93. Allocati N, Di Ilio C, Laurenzi V de. p63/p73 in the control of cell cycle and cell death. Exp. Cell Res. 2012; 318(11):1285-90.
94. Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisà E, Pesole G et al. Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res. 2009; 37(18):6092-104.
95. Suh K, Lacouture M, Gerami P. p63 in Primary Cutaneous Carcinosarcoma. Am J Dermatopathol 2007; 29(4):374-7.
96. Helton ES, Zhu J, Chen X. The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J. Biol. Chem. 2006; 281(5):2533-42.
97. Duijf, Pascal H G, Vanmolkot, Kaate R J, Propping P, Friedl W, Krieger E, McKeon F et al. Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63. Hum. Mol. Genet. 2002; 11(7):799-804.
98. Ghioni P, Bolognese F, Duijf, Pascal H G, van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol. Cell. Biol. 2002; 22(24):8659-68.
99. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ. 2011; 18(9):1487-99.
100. Koster MI, Marinari B, Payne AS, Kantaputra PN, Costanzo A, Roop DR. DeltaNp63 knockdown mice: A mouse model for AEC syndrome. Am. J. Med. Genet. A 2009; 149A(9):1942-7.
101. Mundt HM, Stremmel W, Melino G, Krammer PH, Schilling T, Müller M. Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem. Biophys. Res. Commun. 2010; 396(2):335-41.
102. Zangen R, Ratovitski E, Sidransky D. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 2005; 4(10):1313-5.
103. Dohn M, Zhang S, Chen X. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001; 20(25):3193-205.
104. Di Como, Charles J, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 2002; 8(2):494-501.
105. Pruneri G, Fabris S, Dell'Orto P, Biasi MO, Valentini S, Del Curto B et al. The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J. Pathol. 2005; 206(3):337-45.
106. Jung Y, Qian Y, Yan W, Chen X. Pirh2 E3 ubiquitin ligase modulates keratinocyte differentiation through p63. J. Invest. Dermatol. 2013; 133(5):1178-87.
107. Zhang J, Jun Cho S, Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc. Natl. Acad. Sci. U.S.A. 2010; 107(21):9614-9.
108. Yan W, Zhang Y, Zhang J, Cho S, Chen X. HuR is necessary for mammary epithelial cell proliferation and polarity at least in part via ΔNp63. PLoS ONE 2012; 7(9):e45336.
109. Cho S, Jung Y, Chen X. Poly (C)-binding protein 1 regulates p63 expression through mRNA stability. PLoS ONE 2013; 8(8):e71724.
110. Martynova E, Pozzi S, Basile V, Dolfini D, Zambelli F, Imbriano C et al. Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget 2012; 3(2):132-43.
111. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat. Cell Biol. 2009; 11(12):1451-7.
112. Suh E, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z et al. p63 protects the female germ line during meiotic arrest. Nature 2006; 444(7119):624-8.
113. Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat. Med. 2009; 15(10):1179- 85.
114. Vanbokhoven H, Melino G, Candi E, Declercq W. p63, a story of mice and men. J. Invest. Dermatol. 2011; 131(6):1196-207.
115. Holembowski L, Schulz R, Talos F, Scheel A, Wolff S, Dobbelstein M et al. While p73 is essential, p63 is completely dispensable for the development of the central nervous system. Cell Cycle 2011; 10(4):680-9.
116. D'Aguanno S, Barcaroli D, Rossi C, Zucchelli M, Ciavardelli D, Cortese C et al. p63 Isoforms Regulate Metabolism of Cancer Stem Cells. J. Proteome Res. 2014.
117. Giacobbe A, Bongiorno-Borbone L, Bernassola F, Terrinoni A, Markert EK, Levine AJ et al. p63 regulates glutaminase 2 expression. Cell Cycle 2013; 12(9):1395-405.
118. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7(4):363-73.
119. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, Petherbridge KM et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc. Natl. Acad. Sci. U.S.A. 2006; 103(22):8435-40.
120. Koster MI, Dai D, Roop DR. Conflicting roles for p63 in skin development and carcinogenesis. Cell Cycle 2007; 6(3):269-73.
121. Su X, Chakravarti D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat. Rev. Cancer 2013; 13(2):136-43.
122. Lang GA, Iwakuma T, Suh Y, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119(6):861-72.
123. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137(1):87-98.
124. Muller, Patricia A J, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139(7):1327-41.
125. Muller, Patricia A J, Trinidad AG, Caswell PT, Norman JC, Vousden KH. Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype. J. Biol. Chem. 2014; 289(1):122-32.
126. Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK et al. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res. 2012; 40(2):499-510.
127. Tran MN, Choi W, Wszolek MF, Navai N, Lee IC, Nitti G et al. The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J. Biol. Chem. 2013; 288(5):3275-88.
128. Bailey SG, Cragg MS, Townsend PA. Family friction as ΔNp73 antagonises p73 and p53. Int. J. Biochem. Cell Biol. 2011; 43(4):482-6.
129. Ethayathulla AS, Nguyen HT, Viadiu H. Crystal Structures of the DNA-binding Domain Tetramer of the p53 Tumor Suppressor Family Member p73 Bound to Different Full-site Response Elements. Journal of Biological Chemistry 2013; 288(7):4744-54.
130. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV et al. p73 in Cancer. Genes Cancer 2011; 2(4):491-502.
131. Tschan MP, Grob TJ, Peters UR, Laurenzi VD, Huegli B, Kreuzer KA et al. Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun 2000; 277(1):62-5.
132. Burge S, Teufel DP, Townsley FM, Freund, S. M. V., Bycroft M, Fersht AR. Molecular basis of the interactions between the p73 N terminus and p300: Effects on transactivation and modulation by phosphorylation. Proceedings of the National Academy of Sciences 2009; 106(9):3142-7.
133. Ozaki T, Okoshi R, Ono S, Kubo N, Nakagawara A. Deregulated expression of E2F1 promotes proteolytic degradation of tumor suppressor p73 and inhibits its transcriptional activity. Biochemical and Biophysical Research Communications 2009; 387(1):143-8.
134. Zeng X, Li X, Miller A, Yuan Z, Yuan W, Kwok RP et al. The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Mol. Cell. Biol. 2000; 20(4):1299-310.
135. Downward J, Basu S. YAP and p73: a complex affair. Mol. Cell 2008; 32(6):749-50.
136. Watanabe K, Ozaki T, Nakagawa T, Miyazaki K, Takahashi M, Hosoda M et al. Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. J. Biol. Chem. 2002; 277(17):15113-23.
137. Bálint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation. Oncogene 1999; 18(27):3923-9.
138. Munarriz E, Barcaroli D, Stephanou A, Townsend PA, Maisse C, Terrinoni A et al. PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Mol. Cell. Biol. 2004; 24(24):10593-610.
139. Olmos Y, Brosens JJ, Lam EW. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resistance Updates 2011; 14(1):35-44.
140. Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler J et al. Cyclin-dependent Kinases Phosphorylate p73 at Threonine 86 in a Cell Cycle-dependent Manner and Negatively Regulate p73. Journal of Biological Chemistry 2003; 278(30):27421-31.
141. Watson IR, Blanch A, Lin, Dan C C, Ohh M, Irwin MS. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J. Biol. Chem. 2006; 281(45):34096-103.
142. Rossi M, Laurenzi V de, Munarriz E, Green DR, Liu Y, Vousden KH et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J. 2005; 24(4):836-48.
143. Zhao LY, Liu Y, Bertos NR, Yang X, Liao D. PCAF is a coactivator for p73-mediated transactivation. Oncogene 2003; 22(51):8316-29.
144. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399(6738):814-7.
145. Ren J, Datta R, Shioya H, Li Y, Oki E, Biedermann V et al. p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage. J. Biol. Chem. 2002; 277(37):33758- 65.
146. Sayan BS, Yang AL, Conforti F, Tucci P, Piro MC, Browne GJ et al. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc. Natl. Acad. Sci. U.S.A. 2010; 107(29):12877-82.
147. Bisso A, Collavin L, Del Sal G. p73 as a pharmaceutical target for cancer therapy. Curr. Pharm. Des. 2011; 17(6):578-90.
148. Balint E, Phillips AC, Kozlov S, Stewart CL, Vousden KH. Induction of p57KIP2 expression by p73. Proceedings of the National Academy of Sciences 2002; 99(6):3529-34.
149. Scian MJ, Carchman EH, Mohanraj L, Stagliano, K E R, Anderson, M A E, Deb D et al. Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene 2007; 27(18):2583-93.
150. Innocente SA, Lee JM. p73 is a p53-independent, Sp1-dependent repressor of cyclin B1 transcription. Biochemical and Biophysical Research Communications 2005; 329(2):713-8.
151. Cola A de, Bongiorno-Borbone L, Bianchi E, Barcaroli D, Carletti E, Knight RA et al. FLASH is essential during early embryogenesis and cooperates with p73 to regulate histone gene transcription. Oncogene 2012; 31(5):573-82.
152. Terrinoni A, Ranalli M, Cadot B, Leta A, Bagetta G, Vousden KH et al. p73-alpha is capable of inducing scotin and ER stress. Oncogene 2004; 23(20):3721-5.
153. Wetzel MK, Naska S, Laliberté CL, Rymar VV, Fujitani M, Biernaskie JA et al. p73 Regulates Neurodegeneration and Phospho-Tau Accumulation during Aging and Alzheimer's Disease. Neuron 2008; 59(5):708-21.
154. Cancino GI, Miller FD, Kaplan DR. p73 haploinsufficiency causes tau hyperphosphorylation and tau kinase dysregulation in mouse models of aging and Alzheimer's disease. Neurobiology of Aging 2013; 34(2):387-99.
155. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 2008; 22(19):2677-91.
156. Tissir F, Ravni A, Achouri Y, Riethmacher D, Meyer G, Goffinet AM. DeltaNp73 regulates neuronal survival in vivo. Proc. Natl. Acad. Sci. U.S.A. 2009; 106(39):16871-6.
157. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev. 2010; 24(6):549-60.
158. Niklison-Chirou MV, Steinert JR, Agostini M, Knight RA, Dinsdale D, Cattaneo A et al. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proc. Natl. Acad. Sci. U.S.A. 2013; 110(47):18952-7.
159. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat. Cell Biol. 2013; 15(8):991-1000.
160. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A et al. TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev. 2012; 26(18):2009-14.
161. Seitz SJ, Schleithoff ES, Koch A, Schuster A, Teufel A, Staib F et al. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int. J. Cancer 2010; 126(9):2049-66.
162. Schuster A, Schilling T, Laurenzi V de, Koch AF, Seitz S, Staib F et al. ΔNp73β is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 2010; 9(13):2629-39.
163. Norris MD, Gilbert J, Smith SA, Marshall GM, Salwen H, Cohn SL et al. Expression of the putative tumour suppressor gene, p73, in neuroblastoma and other childhood tumours. Med. Pediatr. Oncol. 2001; 36(1):48-51.
164. Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Bracco E, Papotti M et al. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. J Thorac Oncol 2011; 6(3):473-81.
165. Carastro LM, Lin H, Park HY, Kim D, Radlein S, Hampton KK et al. Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance. Prostate Cancer 2014; 2014(3):1-9.
166. Arvanitis DA, Lianos E, Soulitzis N, Delakas D, Spandidos DA. Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer. Oncol. Rep. 2004; 12(5):1131-7.
167. Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 1999; 18(8):1629-33.
168. Guan M, Peng H, Yu B, Lu Y. p73 Overexpression and angiogenesis in human colorectal carcinoma. Jpn. J. Clin. Oncol. 2003; 33(5):215-20.
169. Dominguez G, Silva JM, Silva J, Garcia JM, Sanchez A, Navarro A et al. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res. Treat. 2001; 66(3):183-90.
170. Diaz R, Gonzalez-Sancho JM, Soldevilla B, Silva J, Garcia JM, Garcia V et al. Differential regulation of TP73 isoforms by 1alpha,25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas. Genes Chromosomes Cancer 2010; 49(12):1135-42.
171. Leupin N, Luthi A, Novak U, Grob TJ, Hugli B, Graber H et al. P73 status in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2004; 45(6):1205-7.
172. Ito Y, Takeda T, Wakasa K, Tsujimoto M, Sakon M, Matsuura N. Expression of p73 and p63 proteins in pancreatic adenocarcinoma: p73 overexpression is inversely correlated with biological aggressiveness. Int. J. Mol. Med. 2001; 8(1):67-71.
173. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7(4):363-73.
174. Soussi T, Ishioka C, Claustres M, Béroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer 2006; 6(1):83-90.
175. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2(2):a001107.
176. Solomon H, Madar S, Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. J. Pathol. 2011; 225(4):475-8.
177. Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L et al. A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer Cell 2012; 22(3):404-15.
178. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445(7128):661-5.
179. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445(7128):656-60.
180. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303(5659):844-8.
181. Lau, L M S, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008; 27(7):997-1003.
182. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007; 26(24):3473-81.
183. Wang J, Zheng T, Chen X, Song X, Meng X, Bhatta N et al. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro. J. Gastroenterol. Hepatol. 2011; 26(2):371-7.
184. Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M et al. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012; 97(11):1722-30.
185. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106(9):3150-9.
186. Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008; 22(4):730-9.
187. Secchiero P, Melloni E, Tiribelli M, Gonelli A, Zauli G. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. J. Leukoc. Biol. 2008; 83(2):434-7.
188. Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM et al. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin. Cancer Res. 2011; 17(4):762-70.
189. Mir R, Tortosa A, Martinez-Soler F, Vidal A, Condom E, Pérez-Perarnau A et al. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int. J. Cancer 2013; 132(7):1525-36.
190. Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev LT et al. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer 2011; 11:211:1-11.
191. Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW, Lawrence DM, Perugini M et al. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Res. 2014; 74(3):921-31.
192. Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castaño E, Acebes J, Giménez-Bonafé P et al. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS ONE 2011; 6(4):e18588.
193. Cinatl J, Speidel D, Hardcastle I, Michaelis M. Resistance acquisition to MDM2 inhibitors. Biochem. Soc. Trans. 2014; 42(4):752-7.
194. Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multidrug-resistant cancer cells. Cell Death Dis 2011; 2:e243.
195. Aziz MH, Shen H, Maki CG. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene 2011; 30(46):4678-86.
196. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef, Lisette G G C, Masucci M et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004; 10(12):1321-8.
197. Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15(3):171-83.
198. Roh J, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett. 2012; 325(1):35-41.
199. Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin. Cancer Res. 2013; 19(18):5092-103.
200. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U.S.A. 2008; 105(10):3933-8.
201. Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. J Hematol Oncol 2012; 5:57.
202. Zou P, Zheng N, Yu Y, Yu S, Sun W, McEachem D et al. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. J Pharm Pharm Sci 2012; 15(2):265-80.
203. Landré V, Rotblat B, Melino S, Bernassola F, Melino G. Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget 2014.
204. Wilson JM, Henderson G, Black F, Sutherland A, Ludwig RL, Vousden KH et al. Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells. Bioorg. Med. Chem. 2007; 15(1):77-86.
205. Devine T, Dai M. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr. Pharm. Des. 2013; 19(18):3248-62.
206. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7(6):547-59.
207. Roxburgh P, Hock AK, Dickens MP, Mezna M, Fischer PM, Vousden KH. Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis 2012; 33(4):791-8.
208. Kojima K, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol. Cancer Ther. 2010; 9(9):2545-57.
209. Tabernero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, Capdevila J et al. A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin. Cancer Res. 2011; 17(19):6313-21.
210. Mandinova A, Lee SW. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med 2011; 3(64):64rv1.
211. Atkins KM, Thomas LL, Barroso-González J, Thomas L, Auclair S, Yin J et al. The Multifunctional Sorting Protein PACS-2 Regulates SIRT1-Mediated Deacetylation of p53 to Modulate p21-Dependent Cell-Cycle Arrest. Cell Rep 2014; 8(5):1545-57.
212. Botta G, De Santis, L P, Saladino R. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins. Curr. Med. Chem. 2012; 19(34):5871-84.
213. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M et al. Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator. Cancer Cell 2008; 13(5):454-63.
214. Nihal M, Ahmad N, Wood GS. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle 2014; 13(4):632-40.
215. Ueno T, Endo S, Saito R, Hirose M, Hirai S, Suzuki H et al. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells. Oncol. Res. 2014; 21(3):155-64.
216. MacCallum SF, Groves MJ, James J, Murray K, Appleyard V, Prescott AR et al. Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep 2013; 3:1275.
217. Kato S, Han S, Liu W, Otsuka K, Shibata H, Kanamaru R et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. U.S.A. 2003; 100(14):8424-9.
218. Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007; 26(15):2243-54.
219. Bykov, Vladimir J N, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002; 8(3):282- 8.
220. Bykov, Vladimir J N, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. 2005; 280(34):30384-91.
221. Wiman KG. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010; 29(30):4245-52.
222. Piantino CB, Reis ST, Viana NI, Silva IA, Morais DR, Antunes AA et al. Prima-1 induces apoptosis in bladder cancer cell lines by activating p53. Clinics (Sao Paulo) 2013; 68(3):297-303.
223. Bykov, Vladimir J N, Zache N, Stridh H, Westman J, Bergman J, Selivanova G et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005; 24(21):3484-91.
224. Rökaeus N, Shen J, Eckhardt I, Bykov, V J N, Wiman KG, Wilhelm MT. PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 2010; 29(49):6442-51.
225. Shalom-Feuerstein R, Serror L, Aberdam E, Müller F, van Bokhoven H, Wiman KG et al. Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET. Proc. Natl. Acad. Sci. U.S.A. 2013; 110(6):2152-6.
226. Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol. Cancer Ther. 2013; 12(11):2331-41.
227. Saha MN, Chen Y, Chen M, Chen G, Chang H. Small molecule MIRA-1 induces in vitro and in vivo antimyeloma activity and synergizes with current anti-myeloma agents. Br. J. Cancer 2014.
228. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. U.S.A. 2008; 105(30):10360-5.
229. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286(5449):2507-10.
230. Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol. 2003; 23(6):2171-81.
231. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003; 22(51):8233-45.
232. Madka V, Zhang Y, Li Q, Mohammed A, Sindhwani P, Lightfoot S et al. p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice. Neoplasia 2013; 15(8):966-74.
233. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc. Natl. Acad. Sci. U.S.A. 2008; 105(17):6302-7.
234. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009; 14(4):597- 606.
235. Schilling T, Kairat A, Melino G, Krammer PH, Stremmel W, Oren M et al. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2010; 394(3):817-23.
236. Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM et al. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 2003; 22(36):5667-76.
237. Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012; 21(6):793- 806.